In this study, we determined the efficacy, safety, pharmacokinetic (PK) and pharmacodynamics (PD) profiles of YF-H-2015005 in combination with granulocyte colony stimulating factor (G-CSF) for CD34+ HSC mobilization in NHL patients. Here, CSF3 is linked to non-Hodgkin lymphoma.